Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Revvity, Inc.
RVTY
NYSE·Healthcare·Medical - Diagnostics & Research·Mkt cap $12.6B
$113.76
▲ +0.82%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$81.22 - $118.30
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 11.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- 86+ year heritage and brand recognition in life sciences and diagnostics with deep customer relationships
- Integrated portfolio combining instruments, reagents, software, and services creating high-margin recurring revenue
- Advanced genomic and next-generation sequencing technologies for oncology, immunodiagnostics, and drug discovery applications
- Global distribution network and regulatory expertise across diagnostics, pharmaceutical, and industrial markets
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Rising demand for genetic screening and early disease detection in diagnostics and personalized medicine
Value
Attractively priced below Life Sciences Tools peer average
Momentum
Hot
+26.9% over 3m
Quality
Strong
Excellent business quality
Dividend
Token
0.25% yield
Smart-money signal
Who's buying RVTY right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 27, 2026
MAY 5, 2026
Reported EPS of $1.06 vs $1.02 consensus (+3.9% surprise). Revenue of $711.1M vs $704.1M expected (+1.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+3.9%
Next: Apr 27, 2026
Revenue trend · last 8Q
—
—
+5%
+2%
+4%
+2%
+6%
+7%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$691.7M
$684.0M
$729.4M
$664.8M
$720.3M
$698.9M
$772.1M
$711.1M
Margins · last 8Q
Gross
—
Operating
—
Profit
5.7%
Wall Street consensus
9 analysts · 33% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
33%
Hold
67%
Sell
0%
Median Price Target
$108.50
▼ -4.6% vs $113.76
Latest: Barclays · May 7, 2026
3 analysts covering